2022-04-28 08:00
Biovica, active in cancer diagnostics, will host a Capital Markets Day on Tuesday May 17, 2022, from 14.00 to 16.30. Biovica is approaching market launch of DiviTum®TKa in the US for the monitoring of metastatic breast cancer treatments. Today, DiviTum®TKa...
2022-03-22 09:30
Biovica, active in cancer diagnostics, today announced that positive results on CDK 4/6 standard therapy from a clinical study at the University of Nebraska Medical Center and Washington University School of Medicine, US, is published in npj Breast Cancer...
2022-03-15 08:00
Significant events during the third quarter Significant events after the end of the period Audiocast: When: 15 March 2022 at 3 PM CET Where: https://tv.streamfabriken.com/biovica-international-q3-2021-2022 Phone numbers: SE: +46850558356, DK: +4582333194...
2022-03-14 18:55
Biovica, active in cancer diagnostics, today announces that the company will establish its own US CLIA lab for the launch of DiviTum®TKa on the US market. Biovica aims to have its lab operational and CLIA certified during third quarter 2022. Biovica...
2022-02-18 14:20
The Nomination Committee prior to the 2022 Annual General Meeting will consist of three members, who shall represent the two shareholders with the highest number of shares who accept the assignment to be part of the Nomination Committee as of December...
2022-02-14 10:40
Biovica, active in cancer diagnostics, today announces that the positive DiviTum®TKa results from the European multicenter study PYTHIA have been published in the highly ranked peer-reviewed scientific journal European Journal of Cancer (EJC). The...
2022-02-07 21:48
Biovica, active in cancer diagnostics, today announces that it has received full feedback from the FDA on its updated 510(k)-application enabling a clear plan for the submission process. Biovica is now aiming for submission in May 2022. As previously...
2021-12-01 07:30
Significant events during the second quarter Significant events after the end of the period Audiocast: When: 1 December 2021 at 3 PM CET Where: https://tv.streamfabriken.com/biovica-international-q2-2021-2022 Phone numbers: SE: +46850558350, DK: +4578150109...
2021-11-24 08:00
Biovica, active in cancer diagnostics, today announces initiation of the TK IMPACT study, an investigator initiated prospective clinical trial at Washington University of St Louis to evaluate the clinical utility of Biovica’s blood-based biomarker...
2021-11-19 16:05
Biovica, active in cancer diagnostics, today announced that results from three different studies using DiviTum®TKa, including a budget impact model, will be presented at the world's largest breast cancer symposium, San Antonio Breast Cancer Symposium...
>4,500
Numbers of patients in studies
28
Publications
32
Pharma Projects